Program Objective: The USAID MVDP and partners have two main thrusts towards a children’s vaccine: protein vaccines with WRAIR, the Malaria Vaccine Initiative (MVI) at PATH, GSK and NIH; and viral vectored vaccines with the Naval Medical Research Institute, and MVI. Currently there are insufficient human and financial resources in any one institution to support a robust malaria vaccine development program. It is only through alliances that the task can be accomplished. Thus, for the most advanced vaccine the alliance is developing, USAID funded the development of processes to make the vaccine at WRAIR, GSK provided the adjuvant, and the vaccine is being field tested by MVI and NIH.
